Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

Rhea-AI Summary

Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the CTOS 2021 Virtual Annual Meeting from November 10-13, 2021. The company will present findings on its drug candidate, INBRX-109, focused on conventional chondrosarcoma and Ewing sarcoma. Presentations include an oral update on safety and efficacy on November 11, and a poster detailing cohort expansion plans. Inhibrx will also participate in multiple upcoming investor conferences in November and December. These presentations are expected to bolster investor confidence and showcase advancements in their oncology pipeline.

Positive

• Presentation of INBRX-109 at the CTOS meeting could increase visibility and investor interest.
• Participation in multiple high-profile investor conferences enhances market presence.

Negative

• None.

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021.

CTOS Virtual Presentation Details:

Title: Safety and Efficacy of the Tetravalent Death Receptor 5 Agonist INBRX-109 in Patients with Conventional Chondrosarcoma: Update from the Phase 1 Expansion Cohort
Lead Author: Vivek Subbiah, MD
Abstract: 1082377, (P 018)
Oral Presentation on Thursday, November 11th at 1:29 p.m. – 1:36 p.m. Eastern Time

Title: Tetravalent Death Receptor 5 Agonist INBRX-109 in Ewing Sarcoma: Planned Phase 1 Cohort Expansion Guided by Preclinical Data
Lead Author: Emily Rowell, PhD
Abstract: 1818985, (P 090)
Poster Presentation on Thursday, November 11th at 2:30 p.m. – 3:15 p.m. Eastern Time

Additionally, the Company will be presenting at the following upcoming virtual investor conferences:

• The Credit Suisse 30^th Annual Healthcare Conference; Tuesday, November 9th at 3:30 p.m. Eastern Time;
• The Stifel 2021 Healthcare Conference; Tuesday, November 16^th at 10:00 a.m. Eastern Time;
• The Jefferies London Healthcare Conference; November 16^th–19^th; Pre-recorded for conference attendees and available post-conference on Inhibrx's website;
• The Evercore ISI 4^th Annual HealthCONx Conference; Wednesday, December 1^st at 3:30 p.m. Eastern Time; and
• The JMP Securities Hematology and Oncology Summit; Tuesday, December 7^th at 2:00 p.m. Eastern Time.

The scientific posters and presentation will be accessible through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The investor conference presentations will be webcast live and will also be accessible through the same link. The webcasts will be available for at least 60 days following the event.

About Inhibrx, Inc.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

Investor and Media Contact:

Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-and-investor-conferences-301413398.html

SOURCE Inhibrx, Inc.

FAQ

What is Inhibrx's upcoming conference schedule for November 2021?

Inhibrx will present at several conferences including the Credit Suisse Healthcare Conference on November 9, Stifel Healthcare Conference on November 16, and the Jefferies London Healthcare Conference from November 16-19.

What topics will Inhibrx present at the CTOS 2021 meeting?

Inhibrx will present the safety and efficacy of INBRX-109 for conventional chondrosarcoma and plans for a cohort expansion in Ewing sarcoma.

When will Inhibrx's presentations at CTOS take place?

The oral presentation is scheduled for November 11 at 1:29 p.m. Eastern Time, followed by a poster presentation on the same day at 2:30 p.m. Eastern Time.